Menu Search
Equities

Emergent BioSolutions Inc

ER4:FRA

Emergent BioSolutions Inc

Actions
  • Price (EUR)1.74
  • Today's Change-0.015 / -0.85%
  • Shares traded385.00
  • 1 Year change-77.58%
  • Beta--
Data delayed at least 15 minutes, as of Apr 30 2024 14:38 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.

  • Revenue in USD (TTM)1.05bn
  • Net income in USD-760.50m
  • Incorporated2003
  • Employees1.60k
  • Location
    Emergent BioSolutions Inc400 Professional Dr, Suite 400GAITHERSBURG 20879United StatesUSA
  • Phone+1 (240) 631-3200
  • Fax+1 (240) 631-3203
  • Websitehttps://emergentbiosolutions.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.